Plus Therapeutics Inc (PSTV) Stock Price, Quote & News

Company Profile

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid...

Industry: Biotechnology

Sector: Healthcare

Phone: 737 255 7194

Fax: 210 974 6901

Website: plustherapeutics.com

Address:

2710 Reed Road, Suite 160, Houston, United States

MedicineMan777 Mar. 21 at 2:15 PM

$PSTV the CNSide business alone is likely worth a meaningful chunk of PSTV. Realistically, you’re looking at something like $40-$80M standalone today (base case), with upside into $100M+

0 · Reply

Vulnerable Mar. 21 at 12:34 AM

$PSTV if REYOBIQ cured cancer it wouldn't years later be told to devise a trial that showed therapeutic benefit. Either the patent for the radiation works or it doesn't. No pop coming, just dilution and costs until it fails a phase 3. Not formula here to tweak.

2 · Reply

nobodyyk Mar. 21 at 12:09 AM

$PSTV I have committed a grave deed. The tree is no more. I have transcended her and devoured her roots. We will settle you in a good place Marc. Fret not.

1 · Reply

Vulnerable Mar. 20 at 11:29 PM

$PSTV how many times is to many? Last big push to by on good news was back when price was .66ish, follow the trail back. MOST stocks he tags are much worse than PSTV meaning PSTV is the most lucrative for SHORTS to see the largest return from a big leg down.

0 · Reply

Vulnerable Mar. 20 at 11:26 PM

$PSTV well said

0 · Reply

Vulnerable Mar. 20 at 11:26 PM

$PSTV well said

0 · Reply

TheLearners Mar. 20 at 9:37 PM

$PSTV @nobodyyk what do you see?

0 · Reply

MedicineMan777 Mar. 20 at 9:06 PM

$PSTV somebody knows something! look at the huge buy lots!

2 · Reply

skiballer8 Mar. 20 at 8:08 PM

$PSTV some pretty big buys just happened. Wonder what that’s about. Maybe a large volume short covering? Insider rush before news? Maybe we’ll see soon.

2 · Reply

MedicineMan777 Mar. 20 at 6:43 PM

$PSTV 5 days for shorts to cover on 12% on exchange and 61% off exchange short interest, even a slight volume momentum after news will spark a rip to one dollar so fast you won't believe.

0 · Reply

Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%

Mar 12, 2026, 4:15 PM EDT - 9 days ago

Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

Feb 25, 2026, 7:30 AM EST - 24 days ago

Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™

Jan 21, 2026, 4:15 PM EST - 2 months ago

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

Jan 14, 2026, 11:36 AM EST - 2 months ago

Penny Cancer Stock Plus Therapeutics Raises $15 Million At Discount, Stock Plunges

Jan 14, 2026, 8:00 AM EST - 2 months ago

Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering

Jan 8, 2026, 7:30 AM EST - 2 months ago

Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases

Dec 11, 2025, 7:30 AM EST - 3 months ago

Plus Therapeutics Expands CNSide Assay Platform to State of California

Dec 9, 2025, 7:30 AM EST - 3 months ago

Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants

Dec 4, 2025, 7:30 AM EST - 3 months ago

Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting

Dec 1, 2025, 7:30 AM EST - 3 months ago

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium

Nov 24, 2025, 7:30 AM EST - 4 months ago

Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases

Nov 20, 2025, 7:30 AM EST - 4 months ago

Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Nov 17, 2025, 7:30 AM EST - 4 months ago

Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Nov 6, 2025, 7:30 AM EST - 4 months ago

Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

Oct 30, 2025, 4:15 PM EDT - 5 months ago

Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights

Oct 21, 2025, 7:30 AM EDT - 5 months ago

Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch

Sep 25, 2025, 7:30 AM EDT - 6 months ago

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Sep 22, 2025, 7:30 AM EDT - 6 months ago

Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT

Sep 18, 2025, 7:30 AM EDT - 6 months ago

Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory

Sep 2, 2025, 4:15 PM EDT - 7 months ago

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 7:30 AM EDT - 7 months ago

Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria

Aug 18, 2025, 7:30 AM EDT - 7 months ago

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

Aug 15, 2025, 7:30 AM EDT - 7 months ago

Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

Aug 14, 2025, 4:15 PM EDT - 7 months ago

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

Aug 14, 2025, 7:30 AM EDT - 7 months ago

Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference

Jul 31, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

Jul 23, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT

Jul 15, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases

Jul 10, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference

Jul 8, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jun 30, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jun 26, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

Jun 25, 2025, 4:15 PM EDT - 9 months ago

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET

Jun 25, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer

Jun 24, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing

May 30, 2025, 4:15 PM EDT - 10 months ago

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

May 23, 2025, 4:15 PM EDT - 10 months ago

Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

May 14, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)

May 8, 2025, 7:00 AM EDT - 11 months ago

Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference

Apr 23, 2025, 8:00 AM EDT - 11 months ago

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

Apr 15, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Mar 20, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

Mar 19, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

Mar 11, 2025, 11:00 AM EDT - 1 year ago

D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

Mar 10, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

Mar 7, 2025, 7:30 AM EST - 1 year ago

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

Mar 6, 2025, 7:30 AM EST - 1 year ago

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

Mar 5, 2025, 4:01 PM EST - 1 year ago

Plus Therapeutics Announces New Employment Inducement Grants

MedicineMan777 Mar. 21 at 2:15 PM

$PSTV the CNSide business alone is likely worth a meaningful chunk of PSTV. Realistically, you’re looking at something like $40-$80M standalone today (base case), with upside into $100M+

0 · Reply

Vulnerable Mar. 21 at 12:34 AM

2 · Reply

nobodyyk Mar. 21 at 12:09 AM

$PSTV I have committed a grave deed. The tree is no more. I have transcended her and devoured her roots. We will settle you in a good place Marc. Fret not.

1 · Reply

Vulnerable Mar. 20 at 11:29 PM

0 · Reply

Vulnerable Mar. 20 at 11:26 PM

$PSTV well said

0 · Reply

Vulnerable Mar. 20 at 11:26 PM

$PSTV well said

0 · Reply

TheLearners Mar. 20 at 9:37 PM

$PSTV @nobodyyk what do you see?

0 · Reply

MedicineMan777 Mar. 20 at 9:06 PM

$PSTV somebody knows something! look at the huge buy lots!

2 · Reply

skiballer8 Mar. 20 at 8:08 PM

$PSTV some pretty big buys just happened. Wonder what that’s about. Maybe a large volume short covering? Insider rush before news? Maybe we’ll see soon.

2 · Reply

MedicineMan777 Mar. 20 at 6:43 PM

$PSTV 5 days for shorts to cover on 12% on exchange and 61% off exchange short interest, even a slight volume momentum after news will spark a rip to one dollar so fast you won't believe.

0 · Reply

Investor1862 Mar. 20 at 6:12 PM

$PSTV this is done

0 · Reply

Jc237 Mar. 20 at 5:05 PM

$PSTV

0 · Reply

Putanasaunders Mar. 20 at 5:04 PM

$PSTV anybody knows if the shorts is still over 21 million shares? fintel shows the same 1 week now !! Time to buy back soon !! Just hodl let them cooook ! They did a great job trying to push it down, if nobody sell they will eat bananas all 2026

0 · Reply

StMichaelTwits Mar. 20 at 4:17 PM

$PSTV I will be back to load heavy in the late fall and you all know why. Still on watch.. 🎵🎵🎵🎵🎵

0 · Reply

MedicineMan777 Mar. 20 at 3:00 PM

$PSTV CNSide diagnostic data could reduce healthcare costs ~40% • That improves: • reimbursement potential • real-world adoption • Focus is shifting from just clinical data → commercial viability

1 · Reply

zzzzzzzzzzzxxx Mar. 20 at 2:47 PM

$PSTV no Marc noooo

0 · Reply

MedicineMan777 Mar. 20 at 2:04 PM

$PSTV CN side giving 40% cost reduction for patients hits health economics, which is what insurers and hospitals care about. • ~40% reduction in LM-related healthcare costs is a huge number

0 · Reply

DIDI_MAGIC Mar. 20 at 1:28 PM

$PSTV Boral Capital price target: $3,00! Let’s rock and roll!

2 · Reply

Love_To_Learn Mar. 20 at 12:56 PM

$PSTV SHIFTED OUR LARGEST SIZE MOVEMENT IN OUR ENTIRE COMPANIES HISTORY AND OUR EXISTENCE YESTERDAY

0 · Reply

Love_To_Learn Mar. 20 at 12:56 PM

$PSTV NOT TOO LONG LONGS * PATIENCE !

2 · Reply

Love_To_Learn Mar. 20 at 12:55 PM

$PSTV BEEN DISTRIBUTING SHARES BACK N FORTH WITH STOP LOSS HUNTER ACTIVATED ON OUR GRID WHILE ACCUMULATING SAME TIME

0 · Reply

Love_To_Learn Mar. 20 at 12:48 PM

$PSTV THE 0.23 0.25 0.28 0.30 4 MARKETS I T IS LINKED WITH US AND THE 0.08 FILLER DOWN UNDER WILL CODE IT FOR MARKETS USING US AS WE SWITCH TRACKS SHIFTING TRAIN TRACKS AND TIMELINES NOW

0 · Reply

Market Cap	42.53M
Revenue (ttm)	5.21M
Net Income (ttm)	-22.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-429.75%
Debt to Equity Ratio	0.19

Volume	4,372,900
Avg Vol	10,867,274
Day's Range	N/A - N/A
Shares Out	171.55M
Stochastic %K	18%
Beta	0.79
Analysts	Strong Sell
Price Target	$6.12